

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (06-03)
Approved for use through 6/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/701,331
				Filing Date	Unassigned
				First Named Inventor	Poncz & Cines
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	2	Attorney Docket Number	UPN 02906AUSA

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
SE	AR	BOOTH et al., "Plasminogen activator inhibitor (PAI-1) in plasma and platelets", <i>Brit. J. Haematol.</i> November, 1988 70:327-333		
	AS	BOOTH et al., "Lysis of platelet-rich thrombi: the role of PAI-1", <i>Ann. N.Y. Acad. Sci.</i> December, 1992 667:70-80		
	AT	DECLERCK et al., "Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay", <i>Blood</i> January, 1998 71:220-225		
	AU	FAY et al., "Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms", <i>Blood</i> January 15, 1994 83:351-356		
	AV	HAYWARD et al., "Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules", <i>Blood</i> February 15, 1997 89:1243-1253		
	AW	HAYWARD et al., "Fibrinogen degradation products in patients with the Quebec platelet disorder", <i>Brit. J. Haematol.</i> May, 1997 97:497-503		
	AX	HOLT et al., "Secretion of plasminogen by washed human platelets", <i>Abstracts Circulation</i> October 1980 62(3):342, No. 1321		
	AY	HOLT et al., "Biochemistry of alpha granule proteins", <i>Sem. Hematol.</i> April, 1985 22:151-163		
SE	AZ	JIANG et al., "Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes", <i>Blood</i> April 1, 1996 87:2775-2781		

Examiner Signature		Date Considered	4/12/06
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/701,331
Filing Date	Unassigned
First Named Inventor	Poncz & Cines
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	UPN 02906AUSA

Sheet	2	of	2
-------	---	----	---

NONPATENT LITERATURE DOCUMENTS

[illegible]


Examiner Signature

Date
Considered

4/12/20

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/088 (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/701,331
				Filing Date	November 4, 2003
				First Named Inventor	Cines and Poncz
				Group Art Unit	1636
				Examiner Name	S. Kaushal
Sheet	1	of	2	Attorney Docket Number	UPN-O2906AUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SK	AA	5,135,736	08-04-1992	Anderson et al.	
	AB	5,169,933	12-08-1992	Anderson et al.	
	AC	5,652,122	07-29-1997	Frankel et al.	
	AD	5,670,617	09-23-1997	Frankel et al.	
	AE	5,674,980	10-07-1997	Frankel et al.	
	AF	5,747,641	05-05-1998	Frankel et al.	
	AG	5,804,604	09-08-1998	Frankel et al.	
SK	AH	6,348,185	02-19-2002	Piwnica-Worms	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
SK	AL	WO-03/035697	05-01-2003	Song et al.		
SK	AM	WO-03/035892	05-01-2003	Ghazal et al.		

Examiner Signature		Date Considered	4/12/06
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/701,331
				Filing Date	November 4, 2003
				First Named Inventor	Cines and Poncz
				Group Art Unit	1636
				Examiner Name	S. Kaushal
Sheet	2	of	2	Attorney Docket Number	UPN-O2906AUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SC	BR	BDEIR et al., "Urokinase mediates fibrinolysis in the pulmonary microvasculature", <i>Blood</i> September 1, 2000 96(5):1820-1826	—
	BS	CHALOIN et al., "Conformations of primary amphipathic carrier peptides in membrane mimicking environments", <i>Biochem. September 16, 1997</i> 36(37):11179-11187	—
	BT	CHALOIN et al., "Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties", <i>Biochem. Biophys. Res. Commun. February 13, 1998</i> 243(2):601-608	
	BU	FAY et al., "Vitronectin inhibits the thrombotic response to arterial injury in mice", <i>Blood</i> March 15, 1999 93(6):1825-1830	
	BV	FUTAKI et al., "Structural variety of membrane permeable peptides", <i>Curr. Protein Pept. Sci. April 2003</i> 4(2):87-96	
	BW	FUTAKI, "Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms", <i>Int. J. Pharm. October 1, 2002</i> 245(1-2):1-7	
	BX	HAYWARD et al., "An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect", <i>Blood</i> June 15, 1996 87(12):4967-4978	
	BY	KUFRIN et al., "Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets", <i>Blood</i> August 1, 2003 102(3):926-933	
	BZ	MORRIS et al., "A peptide carrier for the delivery of biologically active proteins into mammalian cells", <i>Nat. Biotechnol. December 2001</i> 19(12):1173-1176	
	CR	TAYLOR et al., "Delivery of bioactive, gel-isolated proteins into live cells", <i>Electrophoresis</i> May 2003 24(9):1331-1337	
SC	CS	VIVES et al., "TAT peptide internalization: seeking the mechanism of entry", <i>Curr. Protein Pept. Sci. April 2003</i> 4(2):125-132	

Examiner Signature		Date Considered	4/12/06
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.